Advertisement

Dana-Farber Cancer Institute and Astellas Pharma Inc. announce three-year collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer.

Astellas will provide research support and retain the option to obtain from Dana-Farber an exclusive, worldwide license to novel K-Ras inhibitors obtained from the collaboration. Astellas would then conduct further research, development and commercialization.

Nathanael Gray, of the Cancer Biology Department at Dana-Farber and professor at Harvard Medical School, will lead this collaborative research. His laboratory and the Dana-Farber Medicinal Chemistry Core will be joined by the laboratories of Pasi Jänne, and Kwok-Kin Wong, of the Thoracic Oncology Program and co-directors of the Belfer Institute for Applied Cancer Science at Dana-Farber and Professors at Harvard Medical School.

Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement